466 related articles for article (PubMed ID: 12459900)
1. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
3. A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV).
Xie M; Gao L; Li L; Liu W; Yan S
J Inorg Biochem; 2005 Feb; 99(2):546-51. PubMed ID: 15621288
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
5. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
Kordowiak AM; Dabroś W; Kajda B
Horm Metab Res; 2002 Oct; 34(10):556-60. PubMed ID: 12439783
[TBL] [Abstract][Full Text] [Related]
6. In vivo insulin-mimetic activity of [N,N'-1,3-propyl-bis(salicyladimine)]oxovanadium(IV).
Xie M; Xu G; Li L; Liu W; Niu Y; Yan S
Eur J Med Chem; 2007 Jun; 42(6):817-22. PubMed ID: 17343957
[TBL] [Abstract][Full Text] [Related]
7. Vanadium treatment of type 2 diabetes: a view to the future.
Thompson KH; Lichter J; LeBel C; Scaife MC; McNeill JH; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):554-8. PubMed ID: 19162329
[TBL] [Abstract][Full Text] [Related]
8. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
9. Vanadium complexes with mixed O,S anionic ligands derived from maltol: synthesis, characterization, and biological studies.
Monga V; Thompson KH; Yuen VG; Sharma V; Patrick BO; McNeill JH; Orvig C
Inorg Chem; 2005 Apr; 44(8):2678-88. PubMed ID: 15819553
[TBL] [Abstract][Full Text] [Related]
10. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
11. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats.
Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR
Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands.
Katoh A; Matsumura Y; Yoshikawa Y; Yasui H; Sakurai H
J Inorg Biochem; 2009 Apr; 103(4):567-74. PubMed ID: 19162327
[TBL] [Abstract][Full Text] [Related]
13. Insulin-enhancing activity of a dinuclear vanadium complex: 5-chloro-salicylaldhyde ethylenediamine oxovanadium(V) and its permeability and cytotoxicity.
Xie MJ; Yang XD; Liu WP; Yan SP; Meng ZH
J Inorg Biochem; 2010 Aug; 104(8):851-7. PubMed ID: 20434776
[TBL] [Abstract][Full Text] [Related]
14. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
15. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
16. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex.
Wei YB; Yang XD
Biometals; 2012 Dec; 25(6):1261-8. PubMed ID: 23015214
[TBL] [Abstract][Full Text] [Related]
18. Coordination chemistry and insulin-enhancing behavior of vanadium complexes with maltol C6H6O3 structural isomers.
Saatchi K; Thompson KH; Patrick BO; Pink M; Yuen VG; McNeill JH; Orvig C
Inorg Chem; 2005 Apr; 44(8):2689-97. PubMed ID: 15819554
[TBL] [Abstract][Full Text] [Related]
19. Improvement of impaired glucose tolerance by oral administration of vanadyl sulfate by gavage in streptozotocin-induced diabetic rats.
Tsunajima T; Tatsuki R; Satoh K; Yamamoto A; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1997 Nov; 98(2):190-200. PubMed ID: 9467827
[TBL] [Abstract][Full Text] [Related]
20. Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.
Yuen VG; Bhanot S; Battell ML; Orvig C; McNeill JH
Can J Physiol Pharmacol; 2003 Nov; 81(11):1049-55. PubMed ID: 14719040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
